Search
CIGB 2020 Vaccine
go.drugbank.com/drugs/DB15808ExperimentalThe vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba.
Adlinacogene civaparvovec
go.drugbank.com/drugs/DB16788Investigational[L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706]
Luvometinib
go.drugbank.com/drugs/DB21696InvestigationalLuvometinib is under investigation in clinical trial NCT07004075 (FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration).
Glypromate
go.drugbank.com/drugs/DB05633Experimentalglycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by
Sonpiretigene isteparvovec
go.drugbank.com/drugs/DB17844InvestigationalDeveloped by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP).
scAAV9.U7.ACCA
go.drugbank.com/drugs/DB18582InvestigationalDeveloped by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.
Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB16901ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza B virus B/Austria/1359417/2021 BVR-26 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16904ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16916ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16918ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen